The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial.
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bellerophon Theraeutics (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - BMS; MSD
 
Laura Medina Rodriguez
No Relationships to Disclose
 
Sang-We Kim
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
 
Enric Carcereny
Consulting or Advisory Role - AstraZeneca Spain; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche/Genentech; Takeda
Speakers' Bureau - AstraZeneca Spain; BMSi; MSD Oncology; Roche; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche; Takeda
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Indivumed; LG Chem; MSD Oncology
Speakers' Bureau - BMS/Ono; Eisai; Lilly; MSD Oncology
Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Eisai; Immunomet; medpacto; MSD Oncology; Roche/Genentech; Sillajen
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Julio Oliveira
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Janssen; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Janssen; Novartis; Roche
Research Funding - AstraZeneca
 
Pablo Maroto-Rey
Consulting or Advisory Role - Astellas Pharma; BMS; Ipsen
 
Wu-Chou Su
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma (Inst)
 
Mark Voskoboynik
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - AstraZeneca
 
Alejo Rodriguez-Vida
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Merck Sharp & Dohme; Pfizer; Roche
Research Funding - Merck Sharp & Dohme (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Novartis; Pfizer; Roche
 
Luis Costa
No Relationships to Disclose
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Array BioPharma; AstraZeneca; Bio-AI Health; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Incyte; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Takis Biotech; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Maria Amelia Insa Molla
Consulting or Advisory Role - Bristol-Myers Squibb; Pfizer/Astellas; Roche
Expert Testimony - Amgen; AstraZeneca; Bristol-Myers Squibb; Pfizer; Roche
 
Yi Wang
Employment - AstraZeneca
 
Shelby D. Gainer
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Novartis
 
Deepa S Subramaniam
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Martin H Voss
Stock and Other Ownership Interests - CellGenix (I)
Consulting or Advisory Role - Affimed Therapeutics; AVEO; Calithera Biosciences; Eisai; Exelixis; Genentech; Merck; Oncorena; OnQuality Pharmaceuticals; Pfizer
Research Funding - Pfizer
Other Relationship - BMS
(OPTIONAL) Uncompensated Relationships - Aravive; BMS; Genentech/Roche